Literature DB >> 22972370

Blocking of p38 and transforming growth factor β receptor pathways impairs the ability of tolerogenic dendritic cells to suppress murine arthritis.

David Gárate1, Nicole Rojas-Colonelli, Corina Peña, Lorena Salazar, Paula Abello, Bárbara Pesce, Octavio Aravena, Paulina García-González, Carolina H Ribeiro, María C Molina, Diego Catalán, Juan C Aguillón.   

Abstract

OBJECTIVE: Dendritic cells (DCs) modulated with lipopolysaccharide (LPS) are able to reduce inflammation when therapeutically administered into mice with collagen-induced arthritis (CIA). The aim of this study was to uncover the mechanisms that define the tolerogenic effect of short-term LPS-modulated DCs on CIA.
METHODS: Bone marrow-derived DCs were stimulated for 4 hours with LPS and characterized for their expression of maturation markers and their cytokine secretion profiles. Stimulated cells were treated with SB203580 or SB431542 to inhibit the p38 or transforming growth factor β (TGFβ) receptor pathway, respectively, or were left unmodified and, on day 35 after CIA induction, were used to inoculate mice. Disease severity was evaluated clinically. CD4+ T cell populations were counted in the spleen and lymph nodes from inoculated or untreated mice with CIA. CD4+ splenic T cells were transferred from mice with CIA treated with LPS-stimulated DCs or from untreated mice with CIA into other mice with CIA on day 35 of arthritis.
RESULTS: Treatment with LPS-stimulated DCs increased the numbers of interleukin-10 (IL-10)-secreting and TGFβ-secreting CD4+ T cells, but decreased the numbers of Th17 cells. Adoptive transfer of CD4+ T cells from treated mice with CIA reproduced the inhibition of active CIA accomplished with LPS-stimulated DCs. The therapeutic effect of LPS-stimulated DCs and their influence on T cell populations were abolished when the p38 and the TGFβ receptor pathways were inhibited.
CONCLUSION: DCs modulated short-term (4 hours) with LPS are able to confer a sustained cure in mice with established arthritis by re-educating the CD4+ T cell populations. This effect is dependent on the p38 and the TGFβ receptor signaling pathways, which suggests the participation of IL-10 and TGFβ in the recovery of tolerance.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22972370     DOI: 10.1002/art.37702

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  Effect of bone marrow-derived CD11b(+)F4/80 (+) immature dendritic cells on the balance between pro-inflammatory and anti-inflammatory cytokines in DBA/1 mice with collagen-induced arthritis.

Authors:  Jingjing Fu; Lingling Zhang; Shanshan Song; Kangliang Sheng; Ying Li; Peipei Li; Shasha Song; Qingtong Wang; Jianhong Chu; Wei Wei
Journal:  Inflamm Res       Date:  2014-01-24       Impact factor: 4.575

2.  Lipoxin A4-Mediated p38 MAPK Signaling Pathway Protects Mice Against Collagen-Induced Arthritis.

Authors:  Jinyu Li; Qi Sun; Chenying Zheng; Chunxiao Bai; Chuyin Liu; Xueqian Zhao; Peiying Deng; Limin Chai; Yusong Jia
Journal:  Biochem Genet       Date:  2020-11-22       Impact factor: 1.890

3.  Generation of regulatory dendritic cells after treatment with paeoniflorin.

Authors:  Dan Chen; Yingxi Li; Xiaodong Wang; Keqiu Li; Yaqing Jing; Jinghua He; Zhaoyan Qiang; Jingzhi Tong; Ke Sun; Wen Ding; Yi Kang; Guang Li
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

4.  Induction of Tolerogenic Dendritic Cells by a PEGylated TLR7 Ligand for Treatment of Type 1 Diabetes.

Authors:  Tomoko Hayashi; Shiyin Yao; Brian Crain; Victor J Promessi; Luke Shyu; Caroline Sheng; McNancy Kang; Howard B Cottam; Dennis A Carson; Maripat Corr
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

5.  Treatment with Dexamethasone and Monophosphoryl Lipid A Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers Tolerogenic Features.

Authors:  Paulina A García-González; Katina Schinnerling; Alejandro Sepúlveda-Gutiérrez; Jaxaira Maggi; Lorena Hoyos; Rodrigo A Morales; Ahmed M Mehdi; Hendrik J Nel; Lilian Soto; Bárbara Pesce; María Carmen Molina; Miguel Cuchacovich; Milton L Larrondo; Óscar Neira; Diego Francisco Catalán; Catharien M Hilkens; Ranjeny Thomas; Ricardo A Verdugo; Juan C Aguillón
Journal:  Front Immunol       Date:  2016-10-25       Impact factor: 7.561

6.  Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.

Authors:  Woo Sik Kim; Hongmin Kim; Kee Woong Kwon; Sin-Hyeog Im; Bo Ryeong Lee; Sang-Jun Ha; Sung Jae Shin
Journal:  Oncotarget       Date:  2016-06-07

7.  A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines.

Authors:  Paulina García-González; Rodrigo Morales; Lorena Hoyos; Jaxaira Maggi; Javier Campos; Bárbara Pesce; David Gárate; Milton Larrondo; Rodrigo González; Lilian Soto; Verónica Ramos; Pía Tobar; María Carmen Molina; Karina Pino-Lagos; Diego Catalán; Juan Carlos Aguillón
Journal:  J Transl Med       Date:  2013-05-24       Impact factor: 5.531

8.  Dexamethasone preconditioning improves the response of collagen-induced arthritis to treatment with short-term lipopolysaccharide-stimulated collagen-loaded dendritic cells.

Authors:  Corina Peña; David Gárate; Juan Contreras-Levicoy; Octavio Aravena; Diego Catalán; Juan C Aguillón
Journal:  Clin Dev Immunol       Date:  2013-05-29

Review 9.  Gene Expression Profiling of Human Monocyte-derived Dendritic Cells - Searching for Molecular Regulators of Tolerogenicity.

Authors:  Katina Schinnerling; Paulina García-González; Juan Carlos Aguillón
Journal:  Front Immunol       Date:  2015-10-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.